# Experiment 05: Removed 30 Antibodies (Top by Composite Risk)
# Sorted by risk score descending

lirilumab
basiliximab
glembatumumab
urelumab
drozitumab
tremelimumab
nimotuzumab
pembrolizumab
atezolizumab
ipilimumab
ocrelizumab
tralokinumab
rituximab
eldelumab
fezakinumab
tigatuzumab
seribantumab
dinutuximab
enokizumab
lumiliximab
bevacizumab
benralizumab
siltuximab
tabalumab
nivolumab
lebrikizumab
crenezumab
galiximab
veltuzumab
tovetumab
